Navigation Links
Opsona Therapeutics Closes EUR18M Funding
Date:2/18/2009

anised monoclonal antibody (OPN-305) to a key toll-like receptor (TLR) target, has demonstrated efficacy in a number of animal models and will start pivotal clinical trials in 2010.

Florent Gros, managing director, Novartis Venture Fund added, "We are delighted to be working with Opsona Therapeutics and the other investors to assist Opsona in progressing the company's highly innovative technology and approaches towards the clinic. The innate immune system represents a new frontier in targeting inflammatory diseases, and the caliber of the investors in this funding round is a demonstration of Opsona's expertise and capabilities in this highly promising field.'

Opsona has also announced the opening of a new facility in Switzerland. The Swiss laboratory will carry out pivotal assay development and biochemical work for new projects and therapeutics recently acquired by Opsona to expand its pipeline of immunomodulators. The expertise that it intends to grow in Switzerland will complement the existing team and activity in Dublin.

Dr Cormac Kilty, Chairman of Opsona and past Chairman of the Irish Bioindustry Association explains "This is major achievement for any biotechnology company in the current economic climate. Opsona's R&D shows that emerging Irish companies can reach international recognition in biotechnology."

Notes to Editors:

About Opsona Therapeutics

Opsona is a drug development company, focused on novel therapeutic and preventative approaches to autoimmune and inflammatory diseases. The company was founded in 2004 with three of Trinity College Dublin's respected Immunologists (Professors Luke O'Neill, Kingston Mills and Dermot Kelleher). The company is specifically interested in drugs which modulate the innate immune system and its signalling, specifically Toll-Like Receptors (TLR). Opsona has a pipeline of therapeutics in advanced pre-clini
'/>"/>

SOURCE Opsona Therapeutics Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... August 21, 2014 ... has announced the addition of the  "Global ... their offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... therapy, is a means of replacing hormones ... the body. This type of therapy is ...
(Date:8/21/2014)... -- Mathematic studies at the Program for Evolutionary Dynamics ... the Jeffrey Epstein VI Foundation , have shown that ... for elimination. These aggressive cells are the driver mutations that ... map of what to look for when examining tumors, comes ... cells can be extracted from biopsy, it,s very difficult to ...
(Date:8/21/2014)... Sofia, Bulgaria (PRWEB) August 21, 2014 ... was released today by Ontotext . Now ... and semantic analysis of structured and unstructured data is ... of the cost of enterprise technology. Organizations that do ... approaches for data management can use S4 since there ...
(Date:8/20/2014)... analysis of patented university inventions licensed to biotechnology ... to commercialization. To open these roadblocks, the researchers ... during the discovery stage could lead to faster ... frequently derived from discoveries made in university laboratories ... known during clinical trials, which have a high ...
Breaking Biology Technology:Global Hormone Replacement Therapy Market 2014-2018: Key Vendors are Actavis, Bayer, Merck & Co, Novartis and Novo Nordisk 2Science Power Jeffrey Epstein and Harvard University Fund Project to Visually Stop Tumor Growth 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 3Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 4Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3
... of assay of cell-mediated ... immunity, ... data on the monitoring of cell-mediated immunity (CMI) in adult patients,undergoing heart ... demonstrated that ImmuKnow(R) values,appear to closely reflect the immune function of the ...
... REHOVOT, Israel and JERSEY CITY, New Jersey, April ... leader in,the development of microRNA-based diagnostics and therapeutics, ... upcoming annual AACR,conference in San Diego. The posters ... and how they may be applied to develop,objective ...
... Zentaris Inc.,(Nasdaq: AEZS TSX: AEZ;), a global biopharmaceutical ... that David J. Mazzo, Ph.D.,has resigned as President ... the,Board of Directors of AEterna Zentaris, effective immediately. ... of AEterna Zentaris, has been,appointed as the interim ...
Cached Biology Technology:Immune Function in Adult Heart Transplant Patients Reflects Risk for Organ Rejection and Infection 2Immune Function in Adult Heart Transplant Patients Reflects Risk for Organ Rejection and Infection 3Rosetta Genomics to Present Multiple Posters at the Annual American Association of Cancer Research (AACR) Conference 2Rosetta Genomics to Present Multiple Posters at the Annual American Association of Cancer Research (AACR) Conference 3Rosetta Genomics to Present Multiple Posters at the Annual American Association of Cancer Research (AACR) Conference 4Rosetta Genomics to Present Multiple Posters at the Annual American Association of Cancer Research (AACR) Conference 5AEterna Zentaris Announces Changes to its Management Team 2
(Date:8/22/2014)... reductase (DHCR24) is a multifunctional enzyme ... and has neuroprotective and cholesterol-synthesizing activities. ... caused by amyloid β deposition. Dr. ... University in China constructed two recombinant ... DHCR24 expression specifically in neuronal cells. ...
(Date:8/21/2014)... in past decade, GTA still violates Canada,s ozone ... the Greater Toronto Area (GTA) has significantly reduced ... the city continues to violate the Canada-wide standards ... or aggravate health problems such as asthma, emphysema ... of complex photochemical reactions involving volatile organic compounds ...
(Date:8/21/2014)... to ignore, but they are the ultimate source of ... are increasingly dependent on algae, too, to suck up ... to the bottom of the ocean. Now, by using ... have evidence showing that viruses infecting those algae are ... when all else stays essentially the same, and this ...
Breaking Biology News(10 mins):Despite a significant reduction in smog-producing toxins, the Greater Toronto Area still violates Canada's standards for ozone air pollution 2Viruses take down massive algal blooms, with big implications for climate 2
... Human activities are degrading the Amazonian forest at twice ... adds the effects of logging to those of clear-cutting. ... the journal Science , published by AAAS, the ... measuring deforestation across large areas have only been capable ...
... effective vaccines for people with compromised immune systems ... team of researchers, who demonstrated their approach could ... same population of immune cells that HIV destroys ... Hospital of Pittsburgh researchers, working in collaboration with ...
... model systems for understanding fungal diseases, two groups of ... how carbon dioxide (CO2) governs the morphogenic changes that ... invade the human body, and they provide new evidence ... enzymes to control the growth and sexual reproduction of ...
Cached Biology News:Logging doubles threat to the Amazon, rivaling clear-cutting, study suggests 2New vaccine platform may fight infections with causes from influenza to bioterrorism 2New vaccine platform may fight infections with causes from influenza to bioterrorism 3CO2 sensing proves critical for fungal pathogens to adapt to life in air and human hosts 2CO2 sensing proves critical for fungal pathogens to adapt to life in air and human hosts 3